TB R&D Weekly Update: TB Vaccine Efficacy Trial Yields Key Insights and Poor Results

The results of the first TB vaccine efficacy trial in over 90 years was released today showing that the vaccine candidate MVA85A when given as a booster did not provide added protection to infants who had already received BCG. The trial adds scientific value to the field and enhances the field’s understanding and ability in conducting large-scale TB vaccine trials.

Aeras and its partners will be hosting a teleconference to discuss the results and implications on February 6 at 8:30 a.m. EST. Click here for meeting invitation.

Lancet Article “Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial”–click here.

Lancet Commentary “A major event for new tuberculosis vaccines”–click here.

Additional Coverage:

First TB Vaccine Efficacy Study in Almost a Century Provides Key Insights: Vaccine Safe but Does Not Confer Protection, Calls for Redoubling Efforts on Global TB Vaccine Portfolio (Aeras)

Tuberculosis vaccine hopes dashed (BBC)

As Tuberculosis Vaccines Flounder, Developing Nations Join To Fight Drug-Resistant Diseases

Additional R&D News:

Tuberculosis Immunotherapy Grant for Immunoxel Honibe Honey Lozenges

New Drug for an Age-Old Disease

Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis [Review article]. (Int J Tuberc Lung Dis, Feb 2013)

Forsyth scientists gain new understanding of latent tuberculosis

The Tres Cantos Open Lab Foundation and Weill Cornell Medical College Join Forces on Tuberculosis Drug Discovery

Diospyrin inactivates a drug target for tuberculosis in new way

Can (MICs) governments make the global R&D system work for all?

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...